It is currently trading at $1.26 a tad under the 50 day moving average which is $1.36 and impressively lower than the 200 day moving average of $1.42. The 50 day moving average was down $-0.10 whereas the 200 day moving average was down $-0.16 or -11.29%. 74K shares changed hands by the end of trading on Tuesday. Volume was down 62.06% under the stocks average daily volume.
Short traders are feeling a little more bullish on shares of the company lately as evidenced by the motion in short interest. The firm had a fall in short interest of -13.40% as of September 29, 2017 from the last reporting period. Short shares decreased 95,574 over that period. With short interest at 617,447 and short average daily volume at 158,919, the short-interest ratio is 4.0 and the short interest percentage is 0.01% as of September 29.
A few notable investment firms have updated their holdings. As of quarter end Jw Asset Management, LLC had acquired 130,000 shares growing its stake by 15.6%. The value of the investment in ALIM went from $1,170,000 to $1,343,000 a change of 14.8% quarter over quarter. Venbio Select Advisor LLC expanded its investment by buying 100,000 shares an increase of 1.7% as of 06/30/2017. Venbio Select Advisor LLC now holds 5,891,581 shares worth $8,189,000. The total value of its holdings increased 1.0%.
As of the end of the quarter Armistice Capital, LLC had bought a total of 1,464,000 shares growing its position 33.0%. The value of the investment in (ALIM) increased from $6,210,000 to $8,201,000 a change of $1,991,000 quarter to quarter. Livingston Group Asset Management Co (operating As Southport Capital Management) trimmed its holdings by selling 100 shares a decrease of 0.3% in the quarter. Livingston Group Asset Management Co (operating As Southport Capital Management) controls 33,400 shares with a value of $45,000. The value of the position overall is down by 4.3%.
In the last earnings report the EPS was $-0.39 and is expected to be $-0.21 for the current year with 69,050,000 shares currently outstanding. Next quarter’s EPS is expected be $-0.02 and the next full year EPS is projected to be $-0.08.
Alimera Sciences, Inc. (Alimera), launched on June 4, 2003, is a pharmaceutical company. The Company is involved in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Business’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies..